Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?

Przemysław Seweryn; Andrzej Emeryk; Maciej Kupczyk; Radosław Gawlik; Tomasz Dębowski; Grzegorz Sztaba; Rafał Pawliczak

doi:10.5114/pja.2023.131710

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2023
vol. 10

Send email

Copy url:

abstract:

Review paper

Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?

Przemysław Seweryn

¹

,

Andrzej Emeryk

²

,

Maciej Kupczyk

³

,

Radosław Gawlik

⁴

,

Tomasz Dębowski

¹

,

Grzegorz Sztaba

¹

,

Rafał Pawliczak

⁵

Chiesi Poland Sp. z o.o.
Zakład Pediatrii i Pielęgniarstwa Pediatrycznego, Katedra Zintegrowanej Opieki Pielęgniarskiej, Wydział Nauk o Zdrowiu Collegium Academicum, Uniwersytet Medyczny w Lublinie, Lublin, Polska
Klinika Chorób Wewnętrznych, Astmy i Alergii, II Katedra Chorób Wewnętrznych, Wydział Lekarski, Uniwersytet Medyczny w Łodzi, Łódź, Polska
Katedra i Klinika Chorób Wewnętrznych, Alergologii i Immunologii Klinicznej, Wydziału Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, Polska
Zakład Immunopatologii, Wydział Lekarski, Uniwersytet Medyczny w Łodzi, Łódź, Polska

Alergologia Polska – Polish Journal of Allergology 2023; 10, 3: 198–201

DOI: https://doi.org/10.5114/pja.2023.131710

Online publish date: 2023/09/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Seweryn P, Emeryk A, Kupczyk M, et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710.

APA

Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T.,  & Sztaba, G. et al. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), 189-201. https://doi.org/10.5114/pja.2023.131710

Chicago

Seweryn, Przemysław, Andrzej Emeryk, Maciej Kupczyk, Radosław Gawlik, Tomasz Dębowski, Grzegorz Sztaba,  and Rafał Pawliczak. 2023. "Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?". Alergologia Polska - Polish Journal of Allergology 10 (3): 189-201. doi:10.5114/pja.2023.131710.

Harvard

Seweryn, P., Emeryk, A., Kupczyk, M., Gawlik, R., Dębowski, T., Sztaba, G.,  and Pawliczak, R. (2023). Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology, 10(3), pp.189-201. https://doi.org/10.5114/pja.2023.131710

MLA

Seweryn, Przemysław et al. "Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?." Alergologia Polska - Polish Journal of Allergology, vol. 10, no. 3, 2023, pp. 189-201. doi:10.5114/pja.2023.131710.

Vancouver

Seweryn P, Emeryk A, Kupczyk M, Gawlik R, Dębowski T, Sztaba G et al. Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?. Alergologia Polska - Polish Journal of Allergology. 2023;10(3):189-201. doi:10.5114/pja.2023.131710.

PlumX metrics:

The out-of-pocket cost of asthma and chronic obturative pulmonary disease therapy might be a limiting factor of the therapy for many patients in Poland. Does the out-of-pocket copayment influence the therapy choice, specifically where the treatment is reimbursed? Do the therapy cost paid by the patient have any influence on treatment compliance? Will the introduction of the generic medication identical to the innovative drug, but available at lower cost change the therapy adherence? In this review we are trying to answer the aforementioned questions.

keywords:

Formodual – a new therapeutic option in asthma and chronic obturative pulmonary disease treatment with low copayment. Does the therapy cost influence patients’ compliance?

Przemysław Seweryn 1 , Andrzej Emeryk 2 , Maciej Kupczyk 3 , Radosław Gawlik 4 , Tomasz Dębowski 1 , Grzegorz Sztaba 1 , Rafał Pawliczak 5

asthma, treatment, formoterol, beclomethasone

Przemysław Seweryn

¹

,

Andrzej Emeryk

²

,

Maciej Kupczyk

³

,

Radosław Gawlik

⁴

,

Tomasz Dębowski

¹

,

Grzegorz Sztaba

¹

,

Rafał Pawliczak

⁵